Nivolumab

Nivolumab (CAS 946414-94-4), commercially known as Opdivo, is a monoclonal antibody targeting the programmed death receptor-1 (PD-1) protein. By specifically binding PD-1 expressed on T-cells, nivolumab disrupts the PD-1 interaction with ligands PD-L1 and PD-L2, alleviating immune suppressive signaling and restoring anti-tumor T-cell activity. In vitro assays demonstrate nivolumab potently blocks PD-1 interactions with PD-L1 and PD-L2 at low nanomolar IC50 concentrations. It shows minimal non-specific T-cell activation without T-cell receptor stimulation. Nivolumab is widely investigated in cancer immunotherapy research, notably in advanced non-small-cell lung cancer (NSCLC).